(2) DUTIES.—The interagency technical review 
panel shall serve as a ‘‘shadow’’ panel to the Global 
Fund by—
(A) periodically reviewing all proposals re-
ceived by the Global Fund; and 
(B) providing guidance to the United States 
persons who are representatives on the panels, 
committees, and boards of the Global Fund, on 
the technical efficacy, suitability, and appro-
priateness of the proposals, and ensuring that 
such persons are fully informed of technical in-
adequacies or other aspects of the proposals that 
are inconsistent with the purposes of this or any 
other Act relating to the provision of foreign as-
sistance in the area of AIDS. 
(3) MEMBERSHIP.—The interagency technical 
review panel shall consist of qualified medical and de-
velopment experts who are officers or employees of the 
Department of Health and Human Services, the De-
partment of State, and the United States Agency for 
International Development. 
(4) CHAIR.—The Coordinator referred to in 
paragraph (1) shall chair the interagency technical 
review panel. 
(e) MONITORING BY COMPTROLLER GENERAL.—
(1) MONITORING.—The Comptroller General 
shall monitor and evaluate projects funded by the 
Global Fund. 
(2) REPORT.—The Comptroller General shall on 
a biennial basis shall prepare and submit to the ap-
propriate congressional committees a report that con-
tains the results of the monitoring and evaluation de-
scribed in paragraph (1) for the preceding 2-year pe-
riod. 
SEC. 203. VOLUNTARY CONTRIBUTIONS TO INTERNATIONAL 
VACCINE FUNDS. 
(a) VACCINE FUND.—Section 302(k) of the Foreign As-
sistance Act of 1961 (22 U.S.C. 2222(k)) is amended—
(1) by striking ‘‘$50,000,000 for each of the fiscal 
years 2001 and 2002’’ and inserting ‘‘such sums as 
may be necessary for each of the fiscal years 2004 
through 2008’’; and 
(2) by striking ‘‘Global Alliance for Vaccines and 
Immunizations’’ and inserting ‘‘Vaccine Fund’’. 
(b) INTERNATIONAL AIDS VACCINE INITIATIVE.—Sec-
tion 302(l) of the Foreign Assistance Act of 1961 (22 U.S.C. 
2222(l)) is amended by striking ‘‘$10,000,000 for each of 
the fiscal years 2001 and 2002’’ and inserting ‘‘such sums 
as may be necessary for each of the fiscal years 2004 
through 2008’’.
(c) SUPPORT FOR THE DEVELOPMENT OF MALARIA 
VACCINE.—Section 302 of the Foreign Assistance Act of 
1961 (22 U.S.C. 2222)) is amended by adding at the end 
the following new subsection: 
‘‘(m) In addition to amounts otherwise available under 
this section, there are authorized to be appropriated to the 
President such sums as may be necessary for each of the 
fiscal years 2004 through 2008 to be available for United 
States contributions to malaria vaccine development pro-
grams, including the Malaria Vaccine Initiative of the Pro-
gram for Appropriate Technologies in Health (PATH).’’. 
TITLE III—BILATERAL EFFORTS 
Subtitle A—General Assistance and 
Programs 
SEC. 301. ASSISTANCE TO COMBAT HIV/AIDS. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.) is amended—
(1) in section 104(c) (22 U.S.C. 2151b(c)), by 
striking paragraphs (4) through (7); and 
(2) by inserting after section 104 the following 
new section: 
‘‘SEC. 104A. ASSISTANCE TO COMBAT HIV/AIDS. 
‘‘(a) FINDING.—Congress recognizes that the alarming 
spread of HIV/AIDS in countries in sub-Saharan Africa,
the Caribbean, and other developing countries is a major 
global health, national security, development, and humani-
tarian crisis. 
‘‘(b) POLICY.—It is a major objective of the foreign as-
sistance program of the United States to provide assistance 
for the prevention, treatment, and control of HIV/AIDS. 
The United States and other developed countries should pro-
vide assistance to countries in sub-Saharan Africa, the Car-
ibbean, and other countries and areas to control this crisis 
through HIV/AIDS prevention, treatment, monitoring, and 
related activities, particularly activities focused on women 
and youth, including strategies to protect women and pre-
vent mother-to-child transmission of the HIV infection. 
‘‘(c) AUTHORIZATION.—
‘‘(1) IN
GENERAL.—Consistent with section 
104(c), the President is authorized to furnish assist-
ance, on such terms and conditions as the President 
may determine, for HIV/AIDS, including to prevent, 
treat, and monitor HIV/AIDS, and carry out related 
activities, in countries in sub-Saharan Africa, the 
Caribbean, and other countries and areas. 
‘‘(2) ROLE OF NGOS.—It is the sense of Congress 
that the President should provide an appropriate level 
of assistance under paragraph (1) through nongovern-
mental organizations (including faith-based and com-
munity-based organizations) in countries in sub-Sa-
haran Africa, the Caribbean, and other countries and 
areas affected by the HIV/AIDS pandemic. 
‘‘(3) COORDINATION OF ASSISTANCE EFFORTS.—
The President shall coordinate the provision of assist-
ance under paragraph (1) with the provision of re-
lated assistance by the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS), the United Na-
tions Children’s Fund (UNICEF), the World Health 
Organization (WHO), the United Nations Develop-
ment Programme (UNDP), the Global Fund to Fight 
AIDS, Tuberculosis and Malaria and other appro-
priate international organizations (such as the Inter-
national Bank for Reconstruction and Development), 
relevant regional multilateral development institu-
tions, national, state, and local governments of for-
eign countries, appropriate governmental and non-
governmental organizations, and relevant executive 
branch agencies. 
‘‘(d) ACTIVITIES SUPPORTED.—Assistance provided 
under subsection (c) shall, to the maximum extent prac-
ticable, be used to carry out the following activities: 
‘‘(1) PREVENTION.—Prevention of HIV/AIDS 
through activities including—
‘‘(A) programs and efforts that are designed 
or intended to impart knowledge with the exclu-
sive purpose of helping individuals avoid behav-
iors that place them at risk of HIV infection, in-
cluding integration of such programs into health 
programs and the inclusion in counseling pro-
grams of information on methods of avoiding in-
fection of HIV, including delaying sexual debut, 
abstinence, fidelity and monogamy, reduction of 
casual sexual partnering, and where appro-
priate, use of condoms; 
‘‘(B) assistance to establish and implement 
culturally appropriate HIV/AIDS education and 
prevention programs that focus on helping indi-
viduals avoid infection of HIV/AIDS, imple-
mented through nongovernmental organizations, 
including faith-based and community-based or-
ganizations, particularly those organizations 
that utilize both professionals and volunteers 
with appropriate skills, experience, and commu-
nity presence; 
‘‘(C) assistance for the purpose of providing 
voluntary testing and counseling (including the 
incorporation of confidentiality protections with 
respect to such testing and counseling);
‘‘(D) assistance for the purpose of pre-
venting mother-to-child transmission of the HIV 
infection, including medications to prevent such 
transmission and access to infant formula and 
other alternatives for infant feeding; 
‘‘(E) assistance to ensure a safe blood sup-
ply and sterile medical equipment; and 
‘‘(F) assistance to help avoid substance 
abuse and intravenous drug use that can lead to 
HIV infection. 
‘‘(2) TREATMENT.—The treatment and care of 
individuals with HIV/AIDS, including—
‘‘(A) assistance to establish and implement 
programs to strengthen and broaden indigenous 
health care delivery systems and the capacity of 
such systems to deliver HIV/AIDS pharma-
ceuticals and otherwise provide for the treatment 
of individuals with HIV/AIDS, including clin-
ical training for indigenous organizations and 
health care providers; 
‘‘(B) assistance to strengthen and expand 
hospice and palliative care programs to assist 
patients debilitated by HIV/AIDS, their families, 
and the primary caregivers of such patients, in-
‘‘(5) PHARMACEUTICALS.—
‘‘(A) PROCUREMENT.—The procurement of 
HIV/AIDS pharmaceuticals, antiviral therapies, 
and other appropriate medicines, including 
medicines to treat opportunistic infections. 
‘‘(B) MECHANISMS FOR QUALITY CONTROL 
AND SUSTAINABLE SUPPLY.—Mechanisms to en-
sure that such HIV/AIDS pharmaceuticals, 
antiretroviral therapies, and other appropriate 
medicines are quality-controlled and sustainably 
supplied. 
‘‘(C) DISTRIBUTION.—The distribution of 
such 
HIV/AIDS 
pharmaceuticals, 
antiviral 
therapies, and other appropriate medicines (in-
cluding medicines to treat opportunistic infec-
tions) to qualified national, regional, or local or-
ganizations for the treatment of individuals with 
HIV/AIDS in accordance with appropriate HIV/
AIDS testing and monitoring requirements and 
treatment protocols and for the prevention of 
mother-to-child transmission of the HIV infec-
tion. 
‘‘(6) RELATED ACTIVITIES.—The conduct of re-
lated activities, including—
‘‘(A) the care and support of children who 
are orphaned by the HIV/AIDS pandemic, in-
cluding services designed to care for orphaned 
children in a family environment which rely on 
extended family members; 
‘‘(B) improved infrastructure and institu-
tional capacity to develop and manage edu-
cation, prevention, and treatment programs, in-
cluding training and the resources to collect and 
maintain accurate HIV surveillance data to tar-
get programs and measure the effectiveness of 
interventions; and 
‘‘(C) vaccine research and development 
partnership programs with specific plans of ac-
tion to develop a safe, effective, accessible, pre-
ventive HIV vaccine for use throughout the 
world. 
‘‘(7) COMPREHENSIVE HIV/AIDS PUBLIC-PRIVATE 
PARTNERSHIPS.—The establishment and operation of 
public-private partnership entities within countries 
in sub-Saharan Africa, the Caribbean, and other 
countries affected by the HIV/AIDS pandemic that 
are dedicated to supporting the national strategy of 
such countries regarding the prevention, treatment,
and monitoring of HIV/AIDS. Each such public-pri-
vate partnership should—
‘‘(A) support the development, implementa-
tion, and management of comprehensive HIV/
AIDS plans in support of the national HIV/
AIDS strategy; 
‘‘(B) operate at all times in a manner that 
emphasizes efficiency, accountability, and re-
sults-driven programs; 
‘‘(C) engage both local and foreign develop-
ment partners and donors, including businesses, 
government agencies, academic institutions, non-
governmental organizations, foundations, multi-
lateral development agencies, and faith-based or-
ganizations, to assist the country in coordinating 
and implementing HIV/AIDS prevention, treat-
ment, and monitoring programs in accordance 
with its national HIV/AIDS strategy; 
‘‘(D) provide technical assistance, consult-
ant services, financial planning, monitoring and 
evaluation, and research in support of the na-
tional HIV/AIDS strategy; and 
‘‘(E) establish local human resource capac-
ities for the national HIV/AIDS strategy through
the transfer of medical, managerial, leadership, 
and technical skills. 
‘‘(e) ANNUAL REPORT.—
‘‘(1) IN GENERAL.—Not later than January 31 
of each year, the President shall submit to the Com-
mittee on Foreign Relations of the Senate and the 
Committee on International Relations of the House of 
Representatives a report on the implementation of 
this section for the prior fiscal year. 
‘‘(2) REPORT ELEMENTS.—Each report shall in-
clude—
‘‘(A) a description of efforts made by each 
relevant executive branch agency to implement 
the policies set forth in this section, section 
104B, and section 104C; 
‘‘(B) a description of the programs estab-
lished pursuant to such sections; and 
‘‘(C) a detailed assessment of the impact of 
programs established pursuant to such sections, 
including—
‘‘(i)(I) the effectiveness of such pro-
grams in reducing the spread of the HIV 
infection, particularly in women and girls, 
in reducing mother-to-child transmission of
the HIV infection, and in reducing mor-
tality rates from HIV/AIDS; and 
‘‘(II) the number of patients currently 
receiving treatment for AIDS in each coun-
try that receives assistance under this Act. 
‘‘(ii) the progress made toward im-
proving health care delivery systems (in-
cluding the training of adequate numbers of 
staff) and infrastructure to ensure increased 
access to care and treatment; 
‘‘(iii) with respect to tuberculosis, the 
increase in the number of people treated 
and the increase in number of tuberculosis 
patients cured through each program, 
project, or activity receiving United States 
foreign assistance for tuberculosis control 
purposes; and 
‘‘(iv) with respect to malaria, the in-
crease in the number of people treated and 
the increase in number of malaria patients 
cured through each program, project, or ac-
tivity receiving United States foreign assist-
ance for malaria control purposes. 
‘‘(f) FUNDING LIMITATION.—Of the funds made avail-
able to carry out this section in any fiscal year, not more
than 7 percent may be used for the administrative expenses 
of the United States Agency for International Development 
in support of activities described in section 104(c), this sec-
tion, section 104B, and section 104C. Such amount shall 
be in addition to other amounts otherwise available for such 
purposes. 
‘‘(g) DEFINITIONS.—In this section: 
‘‘(1) AIDS.—The term ‘AIDS’ means acquired 
immune deficiency syndrome. 
‘‘(2) HIV.—The term ‘HIV’ means the human 
immunodeficiency virus, the pathogen that causes 
AIDS. 
‘‘(3) HIV/AIDS.—The term ‘HIV/AIDS’ means, 
with respect to an individual, an individual who is 
infected with HIV or living with AIDS. 
‘‘(4) RELEVANT
EXECUTIVE
BRANCH
AGEN-
CIES.—The term ‘relevant executive branch agencies’ 
means the Department of State, the United States 
Agency for International Development, the Depart-
ment of Health and Human Services (including its 
agencies and offices), and any other department or 
agency of the United States that participates in inter-
national HIV/AIDS activities pursuant to the au-
thorities of such department or agency or this Act.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
to a shorter life span, the Administrator of the United 
States Agency for International Development shall, as ap-
propriate—
(1) integrate nutrition programs with HIV/
AIDS activities, generally; 
(2) provide, as a component of an anti-retroviral 
therapy program, support for food and nutrition to 
individuals infected with and affected by HIV/AIDS; 
and 
(3) provide support for food and nutrition for 
children affected by HIV/AIDS and to communities 
and households caring for children affected by HIV/
AIDS. 
(d) ELIGIBILITY FOR ASSISTANCE.—An organization 
that is otherwise eligible to receive assistance under section 
104A of the Foreign Assistance Act of 1961 (as added by 
subsection (a)) or under any other provision of this Act (or 
any amendment made by this Act) to prevent, treat, or 
monitor HIV/AIDS shall not be required, as a condition 
of receiving the assistance, to endorse or utilize a multisec-
toral approach to combatting HIV/AIDS. 
(e) LIMITATION.—No funds made available to carry 
out this Act, or any amendment made by this Act, may 
be used to promote or advocate the legalization or practice 
of prostitution or sex trafficking. Nothing in the preceding
sentence shall be construed to preclude the provision to indi-
viduals of palliative care, treatment, or post-exposure phar-
maceutical prophylaxis, and necessary pharmaceuticals 
and commodities, including test kits, condoms, and, when 
proven effective, microbicides. 
(f) LIMITATION.—No funds made available to carry 
out this Act, or any amendment made by this Act, may 
be used to provide assistance to any group or organization 
that does not have a policy explicitly opposing prostitution 
and sex trafficking. 
SEC. 302. ASSISTANCE TO COMBAT TUBERCULOSIS. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by section 
301 of this Act, is further amended by inserting after section 
104A the following new section: 
‘‘SEC. 104B. ASSISTANCE TO COMBAT TUBERCULOSIS. 
‘‘(a) FINDINGS.—Congress makes the following find-
ings: 
‘‘(1) Congress recognizes the growing inter-
national problem of tuberculosis and the impact its 
continued existence has on those countries that had 
previously largely controlled the disease. 
‘‘(2) Congress further recognizes that the means 
exist to control and treat tuberculosis through ex-
panded use of the DOTS (Directly Observed Treat-
ment Short-course) treatment strategy, including 
DOTS-Plus to address multi-drug resistant tuber-
culosis, and adequate investment in newly created 
mechanisms to increase access to treatment, including 
the Global Tuberculosis Drug Facility established in 
2001 pursuant to the Amsterdam Declaration to Stop 
TB and the Global Alliance for TB Drug Develop-
ment. 
‘‘(b) POLICY.—It is a major objective of the foreign as-
sistance program of the United States to control tuber-
culosis, including the detection of at least 70 percent of the 
cases of infectious tuberculosis, and the cure of at least 85 
percent of the cases detected, not later than December 31, 
2005, in those countries classified by the World Health Or-
ganization as among the highest tuberculosis burden, and 
not later than December 31, 2010, in all countries in which 
the United States Agency for International Development 
has established development programs. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of tuberculosis.
‘‘(d) COORDINATION.—In carrying out this section, the 
President shall coordinate with the World Health Organiza-
tion, the Global Fund to Fight AIDS, Tuberculosis, and 
Malaria, and other organizations with respect to the devel-
opment and implementation of a comprehensive tuber-
culosis control program. 
‘‘(e) PRIORITY TO DOTS COVERAGE.—In furnishing 
assistance under subsection (c), the President shall give pri-
ority to activities that increase Directly Observed Treat-
ment Short-course (DOTS) coverage and treatment of 
multi-drug resistant tuberculosis where needed using 
DOTS-Plus, including funding for the Global Tuberculosis 
Drug Facility, the Stop Tuberculosis Partnership, and the 
Global Alliance for TB Drug Development. In order to meet 
the requirement of the preceding sentence, the President 
should ensure that not less than 75 percent of the amount 
made available to carry out this section for a fiscal year 
should be expended for antituberculosis drugs, supplies, di-
rect patient services, and training in diagnosis and treat-
ment for Directly Observed Treatment Short-course (DOTS) 
coverage and treatment of multi-drug resistant tuberculosis 
using DOTS-Plus, including substantially increased fund-
ing for the Global Tuberculosis Drug Facility. 
‘‘(f) DEFINITIONS.—In this section:
‘‘(1) DOTS.—The term ‘DOTS’ or ‘Directly Ob-
served Treatment Short-course’ means the World 
Health Organization-recommended strategy for treat-
ing tuberculosis. 
‘‘(2) 
DOTS-PLUS.—The 
term 
‘DOTS-Plus’ 
means a comprehensive tuberculosis management 
strategy that is built upon and works as a supple-
ment to the standard DOTS strategy, and which takes 
into account specific issues (such as use of second line 
anti-tuberculosis drugs) that need to be addressed in 
areas where there is high prevalence of multi-drug re-
sistant tuberculosis. 
‘‘(3) GLOBAL
ALLIANCE
FOR
TUBERCULOSIS 
DRUG DEVELOPMENT.—The term ‘Global Alliance for 
Tuberculosis Drug Development’ means the public-
private partnership that brings together leaders in 
health, science, philanthropy, and private industry to 
devise new approaches to tuberculosis and to ensure 
that new medications are available and affordable in 
high tuberculosis burden countries and other affected 
countries. 
‘‘(4) GLOBAL TUBERCULOSIS DRUG FACILITY.—
The term ‘Global Tuberculosis Drug Facility (GDF)’ 
means the new initiative of the Stop Tuberculosis
Partnership to increase access to high-quality tuber-
culosis drugs to facilitate DOTS expansion. 
‘‘(5) STOP
TUBERCULOSIS
PARTNERSHIP.—The 
term ‘Stop Tuberculosis Partnership’ means the part-
nership of the World Health Organization, donors in-
cluding the United States, high tuberculosis burden 
countries, multilateral agencies, and nongovernmental 
and technical agencies committed to short- and long-
term measures required to control and eventually 
eliminate tuberculosis as a public health problem in 
the world.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds available 
under section 104(c) of the Foreign Assistance Act of 
1961 (22 U.S.C. 2151b(c)) for such purpose or under 
any other provision of that Act, there are authorized 
to be appropriated to the President, from amounts 
authorized to be appropriated under section 401, such 
sums as may be necessary for each of the fiscal years 
2004 through 2008 to carry out section 104B of the 
Foreign Assistance Act of 1961, as added by sub-
section (a). 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to the authorization of appropria-
tions under paragraph (1) are authorized to remain 
available until expended. 
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unobli-
gated balances of funds made available for fiscal year 
2001, 2002, or 2003 under section 104(c)(7) of the 
Foreign 
Assistance 
Act 
of 
1961 
(22 
U.S.C. 
2151b(c)(7) (as in effect immediately before the date 
of enactment of this Act) shall be transferred to, 
merged with, and made available for the same pur-
poses as funds made available for fiscal years 2004 
through 2008 under paragraph (1). 
SEC. 303. ASSISTANCE TO COMBAT MALARIA. 
(a) AMENDMENT OF THE FOREIGN ASSISTANCE ACT 
OF 1961.—Chapter 1 of part I of the Foreign Assistance 
Act of 1961 (22 U.S.C. 2151 et seq.), as amended by sections 
301 and 302 of this Act, is further amended by inserting 
after section 104B the following new section: 
‘‘SEC. 104C. ASSISTANCE TO COMBAT MALARIA. 
‘‘(a) FINDING.—Congress finds that malaria kills more 
people annually than any other communicable disease ex-
cept tuberculosis, that more than 90 percent of all malaria 
cases are in sub-Saharan Africa, and that children and 
women are particularly at risk. Congress recognizes that 
there are cost-effective tools to decrease the spread of ma-
laria and that malaria is a curable disease if promptly di-
agnosed and adequately treated. 
‘‘(b) POLICY.—It is a major objective of the foreign as-
sistance program of the United States to provide assistance 
for the prevention, control, and cure of malaria. 
‘‘(c) AUTHORIZATION.—To carry out this section and 
consistent with section 104(c), the President is authorized 
to furnish assistance, on such terms and conditions as the 
President may determine, for the prevention, treatment, 
control, and elimination of malaria. 
‘‘(d) COORDINATION.—In carrying out this section, the 
President shall coordinate with the World Health Organiza-
tion, the Global Fund to Fight AIDS, Tuberculosis, and 
Malaria, the Department of Health and Human Services 
(the Centers for Disease Control and Prevention and the 
National Institutes of Health), and other organizations 
with respect to the development and implementation of a 
comprehensive malaria control program.’’. 
(b) AUTHORIZATION OF APPROPRIATIONS.—
(1) IN GENERAL.—In addition to funds available 
under section 104(c) of the Foreign Assistance Act of 
1961 (22 U.S.C. 2151b(c)) for such purpose or under 
any other provision of that Act, there are authorized 
to be appropriated to the President, from amounts 
authorized to be appropriated under section 401, such
sums as may be necessary for fiscal years 2004 
through 2008 to carry out section 104C of the Foreign 
Assistance Act of 1961, as added by subsection (a), 
including for the development of anti-malarial phar-
maceuticals by the Medicines for Malaria Venture. 
(2) AVAILABILITY OF FUNDS.—Amounts appro-
priated pursuant to paragraph (1) are authorized to 
remain available until expended. 
(3) TRANSFER OF PRIOR YEAR FUNDS.—Unobli-
gated balances of funds made available for fiscal year 
2001, 2002, or 2003 under section 104(c) of the For-
eign Assistance Act of 1961 (22 U.S.C. 2151b(c) (as 
in effect immediately before the date of enactment of 
this Act) and made available for the control of ma-
laria shall be transferred to, merged with, and made 
available for the same purposes as funds made avail-
able for fiscal years 2004 through 2008 under para-
graph (1). 
(c) CONFORMING AMENDMENT.—Section 104(c) of the 
Foreign Assistance Act of 1961 (22 U.S.C. 2151b(c)), as 
amended by section 301 of this Act, is further amended by 
adding after paragraph (3) the following: 
‘‘(4) RELATIONSHIP
TO
OTHER
LAWS.—Assistance 
made available under this subsection and sections 104A, 
104B, and 104C, and assistance made available under
chapter 4 of part II to carry out the purposes of this sub-
section and the provisions cited in this paragraph, may be 
made available notwithstanding any other provision of law 
that restricts assistance to foreign countries, except for the 
provisions of this subsection, the provisions of law cited in 
this paragraph, subsection (f), section 634A of this Act, and 
provisions of law that limit assistance to organizations that 
support or participate in a program of coercive abortion 
or involuntary sterilization included under the Child Sur-
vival and Health Programs Fund heading in the Consoli-
dated Appropriations Resolution, 2003 (Public Law 108–
7).’’. 
SEC. 304. PILOT PROGRAM FOR THE PLACEMENT OF 
HEALTH CARE PROFESSIONALS IN OVERSEAS 
AREAS SEVERELY AFFECTED BY HIV/AIDS, TU-
BERCULOSIS, AND MALARIA. 
(a) IN GENERAL.—The President should establish a 
program to demonstrate the feasibility of facilitating the 
service of United States health care professionals in those 
areas of sub-Saharan Africa and other parts of the world 
severely affected by HIV/AIDS, tuberculosis, and malaria. 
(b) REQUIREMENTS.—Participants in the program 
shall—
(1) provide basic health care services for those 
infected and affected by HIV/AIDS, tuberculosis, and 
malaria in the area in which they are serving; 
(2) provide on-the-job training to medical and 
other personnel in the area in which they are serving 
to strengthen the basic health care system of the af-
fected countries; 
(3) provide health care educational training for 
residents of the area in which they are serving; 
(4) serve for a period of up to three years; and 
(5) meet the eligibility requirements in sub-
section (d). 
(c) ELIGIBILITY REQUIREMENTS.—To be eligible to 
participate in the program, a candidate shall—
(1) be a national of the United States who is a 
trained health care professional and who meets the 
educational and licensure requirements necessary to 
be such a professional such as a physician, nurse, 
physician assistant, nurse practitioner, pharmacist, 
other type of health care professional, or other indi-
vidual determined to be appropriate by the President; 
or 
(2) be a retired commissioned officer of the Pub-
lic Health Service Corps.
(d) RECRUITMENT.—The President shall ensure that 
information on the program is widely distributed, includ-
ing the distribution of information to schools for health pro-
fessionals, hospitals, clinics, and nongovernmental organi-
zations working in the areas of international health and 
aid. 
(e) PLACEMENT OF PARTICIPANTS.—
(1) IN GENERAL.—To the maximum extent prac-
ticable, participants in the program shall serve in the 
poorest areas of the affected countries, where health 
care needs are likely to be the greatest. The decision 
on the placement of a participant should be made in 
consultation with relevant officials of the affected 
country at both the national and local level as well 
as with local community leaders and organizations. 
(2) COORDINATION.—Placement of participants 
in the program shall be coordinated with the United 
States Agency for International Development in coun-
tries in which that Agency is conducting HIV/AIDS, 
tuberculosis, or malaria programs. Overall coordina-
tion of placement of participants in the program 
shall be made by the Coordinator of United States 
Government Activities to Combat HIV/AIDS Globally 
(as described in section 1(f) of the State Department